title: Irinotecan-induced immune thrombocytopenia.
abstract: BACKGROUND
  Irinotecan is currently used as second-line chemotherapy for advanced colorectal cancer. We report a case of severe thrombocytopenia after Irinotecan, suggesting an immune mechanism, in a 53-year-old patient.
  
  
  METHODS
  The patient's sera were screened for platelet antibodies with an indirect platelet immunofluorescence test (PIIFT). The monoclonal antibody immobilization of platelet antigen assay (MAIPA) was used to characterize the antibody target.
  
  
  RESULTS
  We detected an IgG platelet antibody in the patient's serum in the presence of Irinotecan by means of PIIFT, and not in the presence of SN-38, its active metabolite. The specificity of the binding was asserted after CD32 MoAb blockade. The platelet binding site could not be strictly identified with MAIPA and immunoblotting but GpIIb/IIIa can be excluded after experiments with Glanzmann platelets.
  
  
  CONCLUSIONS
  This case can be considered the first documented Irinotecan-induced immune thrombocytopenia.
authors.affiliation: FSMSIT, Hôpital Paul Brousse, Villejuif, France.
authors.forename: L
authors.initials: L
authors.lastname: Bozec
authors.forename: P
authors.initials: P
authors.lastname: Bierling
authors.forename: P
authors.initials: P
authors.lastname: Fromont
authors.forename: F
authors.initials: F
authors.lastname: Lévi
authors.forename: P
authors.initials: P
authors.lastname: Debat
authors.forename: E
authors.initials: E
authors.lastname: Cvitkovic
authors.forename: J L
authors.initials: JL
authors.lastname: Misset
mesh_terms: D000230:Adenocarcinoma / Q000175:diagnosis / Q000188:drug therapy*; D000972:Antineoplastic Agents, Phytogenic / Q000009:adverse effects* / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001792:Blood Platelets / Q000276:immunology; D002166:Camptothecin / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D003110:Colonic Neoplasms / Q000175:diagnosis / Q000188:drug therapy*; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D007074:Immunoglobulin G / Q000032:analysis; D000077146:Irinotecan; D002955:Leucovorin / Q000008:administration & dosage; D008113:Liver Neoplasms / Q000556:secondary; D008297:Male; D008875:Middle Aged; D009944:Organoplatinum Compounds / Q000008:administration & dosage; D000077150:Oxaliplatin; D013921:Thrombocytopenia / Q000139:chemically induced* / Q000276:immunology
chemical_list: D000972:Antineoplastic Agents, Phytogenic; D007074:Immunoglobulin G; D009944:Organoplatinum Compounds; D000077150:Oxaliplatin; D000077146:Irinotecan; D002955:Leucovorin; D005472:Fluorouracil; D002166:Camptothecin